Sartorius scoops double award at Fisher Scientific European Sales Conference
Company also promoted to Platinum supplier status in Europe.
Sartorius was a double award winner at the Fisher Scientific European Sales Conference in Malta, picking up the awards for Supplier Excellence and Best Booth. These awards coincided with the formal announcement of the promotion of Sartorius to Platinum supplier status in Europe.
The Supplier Excellence Award recognized the excellent cooperation between Fisher Scientific and Sartorius. The year 2017 saw the Sartorius business with Fisher Scientific increase. The award also recognizes Sartorius for supply chain excellence, product quality and marketing support. The Best Booth award, which is voted for by the Fisher Scientific Commercial team, is awarded to the supplier whose booth best incorporates the four values of Fisher Scientific: involvement, intensity, innovation and integrity.
John Collings, European Category Director at Fisher Scientific, announced the change in partnership and explained what it means for the relationship between the two companies. “This change is a significant long-term investment from both companies and will now help us move forward in strategic partnership. This promotion to Platinum will also drive ambitious revenue growth targets, through increased marketing, commercial, supply chain and strategic plans.”
Daniela Winzker-Demes, Sartorius’ Vice President of LPS Sales & Services EMEA, and John Bryson, Director Channel Management Europe, proudly accepted the awards. “The new status is an incentive for us to intensify our cooperation to continuously improve our customers’ experience," said Winzker-Demes. John Bryson commented: “These awards, and the move to Platinum status, reflect our shared success and close partnership with Fisher Scientific. We look forward to another successful year in 2018 as we work together to drive further growth and deliver solutions to our customers.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.